Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage

Author： Macdonald R Loch  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.11, 2008-11, pp. : 1761-1767

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endothelin and Subarachnoid Hemorrhage-Induced Cerebral Vasospasm: Pathogenesis and Treatment

By  

Current Medicinal Chemistry, Vol. 11, Iss. 13, 2004-07 ,pp. : 1779-1791

Bentham Science Publishers

Access to resources Recommend Favorite

Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

By Giersbergen Paul   Dingemanse Jasper  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 151-158

Springer Publishing Company

Access to resources Recommend Favorite

Protein kinase C and are involved in the development of vasospasm after subarachnoid hemorrhage

By Nishizawa S.   Obara K.   Nakayama  

European Journal of Pharmacology, Vol. 398, Iss. 1, 2000-06 ,pp. : 113-119

Elsevier

Access to resources Recommend Favorite

Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies

By  

Current Drug Delivery, Vol. 14, Iss. 6, 2017-09 ,pp. : 843-852

Bentham Science Publishers

Access to resources Recommend Favorite

Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

By Horn Evelyn M   Widlitz Allison C   Barst Robyn J  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1483-1492

Informa Healthcare

Access to resources Recommend Favorite